Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.24 -0.12 (-0.25%)
Streaming Delayed Price Updated: 12:45 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,608,859
Open 48.84
Bid (Size) 49.24 (100)
Ask (Size) 49.25 (500)
Prev. Close 49.37
Today's Range 48.63 - 49.35
52wk Range 43.08 - 93.80
Shares Outstanding N/A
Dividend Yield 2.37%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth
In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion... 
Via MarketMinute
Topics Earnings Economy
News headline image
NVO Stock Generates Retail Buzz After European Commission Approves 7.2 MG Once-Weekly Dose Of Wegovy Injection ↗
The approval follows a positive recommendation from the European Medicines Agency and is supported by data from clinical trials involving more than 1,400 participants. 
Via Stocktwits
Topics Lawsuit

Performance

YTD
-6.0%
-6.0%
1 Month
-18.8%
-18.8%
3 Month
+3.6%
+3.6%
6 Month
-10.1%
-10.1%
1 Year
-40.2%
-40.2%

More News

Read More
News headline image
2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗
Via The Motley Fool
Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report ↗
Via Stocktwits
HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In? ↗
Via Stocktwits
News headline image
Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy? ↗
Via The Motley Fool
News headline image
Got $500? 2 Pharma Stocks to Buy and Hold Forever. ↗
Via The Motley Fool
News headline image
Novo Nordisk To Meet Wegovy Pill Demand In US Before Expanding To Avoid Supply Shortage, Says CEO Doustdar ↗
Via Stocktwits
Topics Lawsuit
News headline image
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? ↗
Via Stocktwits
News headline image
Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. ↗
Via The Motley Fool
News headline image
Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs ↗
Via Benzinga
News headline image
Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly ↗
Via Stocktwits
Topics Intellectual Property
News headline image
The Greenland Gambit: Inside the Transatlantic Tariff Shock and the Future of Arctic Sovereignty
Via MarketMinute
Topics Bonds Economy Government
News headline image
Disney Has Its Next CEO ↗
Via The Motley Fool
News headline image
Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip. ↗
Via The Motley Fool
News headline image
Biotech Beat Nvidia in 2025. Can It Do It Again? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗
Via The Motley Fool
News headline image
Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know ↗
Via The Motley Fool
News headline image
AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗
Via Stocktwits
News headline image
Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗
Via The Motley Fool
News headline image
Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit ↗
Via The Motley Fool
Topics Artificial Intelligence Lawsuit Stocks
News headline image
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast? ↗
Via The Motley Fool
Topics Intellectual Property Lawsuit
News headline image
Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment? ↗
Via The Motley Fool
Topics Intellectual Property

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 49.24
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 02/18/26 12:45 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.